Hearing Loss Trial, Recruiting NCT05679271 Sponsor: University Hospital, Bordeaux Condition: Hearing Loss
Back to Hearing Loss

Hearing Loss Trial, Recruiting

NCT05679271
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have a pulsating/whooshing sound in your ear (called pulsatile tinnitus) that significantly affects your daily life
  • A scan has confirmed that your tinnitus is caused by an abnormal connection between arteries and veins near your brain, called a dural arteriovenous fistula (DAVF)
  • Your DAVF is a mild type (Type I or IIa based on a standard medical classification system) as confirmed by a specialised blood vessel scan
  • Your DAVF is located in a specific area at the back/side of the brain involving certain large blood vessels (the sigmoid, lateral, or posterior longitudinal sinus)
  • The abnormal connection is small enough to be treated with no more than two small mesh tubes (stents)
  • If you are a woman who could become pregnant, you must use reliable contraception throughout the study
  • You are covered by health insurance
  • You are willing and able to sign a consent form agreeing to take part

Who may not be able to join:

  • Your DAVF cannot be treated through a minimally invasive procedure through the blood vessels
  • Your DAVF is a more severe type (Type IIb or higher on the standard classification scale)
  • Your DAVF involves a blood vessel that is too narrow or blocked to allow placement of a stent
  • You have had inflammation or a blood clot in the affected blood vessel within the last 3 months
  • Your DAVF has already been treated with surgery or radiation therapy
  • You have more than one DAVF
  • The large blood vessel on the opposite side of the head is absent or blocked
  • You have a medical reason that prevents you from using the specific stent device used in this trial (confirm with trial site)
  • You are currently taking part in another clinical study testing a medical device
  • You are unable to attend follow-up appointments at the trial centre at 6 months
  • You have a known allergy to heparin, aspirin, warfarin, or other blood-thinning or antiplatelet medications
  • You have had any surgery or minimally invasive procedure in the 30 days before the study procedure
  • You have had a bleed in or around your brain in the 30 days before the study procedure
  • You have a known serious allergy to the dye used in medical scans (contrast agents)
  • You have a known sensitivity or allergy to nickel, titanium, or related metals (which are used in the stent)
  • You have significant kidney problems, as shown by specific blood test results (confirm with trial site for exact values)
  • You have any reason that prevents you from having an MRI scan or blood vessel scan
  • You are pregnant, breastfeeding, or planning to become pregnant during the study period
  • You are unable to understand what the study involves or are unwilling to sign a consent form
  • You are under legal guardianship or protection

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +33 556 79 56 04

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
22 August 2024
Est. completion
1 December 2027

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Cognard's classification grade

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov